Upcoming event
EAU UROonco: A meeting steered by the EAU Section of Oncological Urology
Back

Tag: ASCO21

Pembro in combination with Gem and concurrent hypofractionated RT as bladder sparing treatment for MIBC

ACIS study

Phase-2 trial of gemcitabine, cisplatin + nivolumab with selective bladder sparing in MIBC patients

PEACE-1 trial

VISION study

Phase-2 trial of gemcitabine, cisplatin + nivolumab with selective bladder sparing in MIBC patients

PEACE-1 trial

Phase-III study of lutetium-177-PSMA-617 in mCRPC patients

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study